STA-21 Topical Efficacy on Psoriasis

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The clinical assessment of patients with plaque-type psoriasis is performed by open, intrapatient comparison of 0.2% STA-21 with vehicle(Vaseline) alone within a 2 week period.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kochi University

Criteria

Inclusion Criteria:

• A history of plaque psoriasis for a minimum of 2 years.

• In good general health, as evidenced by blood, renal function, and liver function tests conducted before commencing the study.

• Patients of childbearing age who agreed to continue using birth control for the duration of the study.

• Men or women between 20 and 80 years old.

Exclusion Criteria:

• Chronic plaque psoriasis involving >40% of the body surface.

• Pustular or generalized erythrodermic psoriasis.

• Use of medications that might affect the psoriasis during the study

• Systemic therapy for psoriasis within 60 d of baseline.

• UV therapy within 21 d of baseline.

• Topical therapy within 14 d of baseline.

• Positive for HIV, hepatitis B, or hepatitis C.

• Clinically significant laboratory abnormality in blood, renal function, or liver function.

• Lactating, pregnant, or planning to become pregnant.

• Participation in another clinical trial in the last 30 d.

• Unwillingness to comply with the study protocol.

• Any other condition that in the opinion of the investigators could compromise the study.